5 Year Observation of Patients With PORTICO Valves

NCT ID: NCT01802788

Last Updated: 2025-02-11

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1032 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-04-16

Study Completion Date

2022-10-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical investigation is to further assess the performance and safety profile of the commercially-available Portico™ TAVI System in patients with severe symptomatic aortic stenosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an international multicenter, prospective, non-randomized clinical investigation without concurrent or matched control, designed to assess the mid-term safety and performance of the Portico valve in patients with severe symptomatic aortic stenosis whom are high risk for surgical valve replacement. The primary endpoint is 1 year all-cause mortality. In addition, the performance and safety profile of the Portico valve will be further evaluated at 30 days, 1 year, and annually through 5 years post-implant.

The investigation will be conducted at approximately 65 centers in approximately 15 countries in Europe, Middle-East, Africa, Canada, Australia and New Zealand.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Valve Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort A

Patients implanted with a Portico valve after CE mark

St Jude Medical Portico replacement aortic valve

Intervention Type DEVICE

Transcatheter Aortic Valve Implant

Intervention Type PROCEDURE

Cohort B

Patients implanted in previous SJM-sponsored premarket studies

St Jude Medical Portico replacement aortic valve

Intervention Type DEVICE

Transcatheter Aortic Valve Implant

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

St Jude Medical Portico replacement aortic valve

Intervention Type DEVICE

Transcatheter Aortic Valve Implant

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TAVI Transcatheter Aortic Valve Replacement TAVR

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient has signed the Patient Informed Consent prior to participating in the clinical investigation.
* Patient has been referred for a Portico Valve implant as per Heart Team decision or patient has received a Portico Valve as per participation in an SJM sponsored regulatory or first-in-human trial.
* Patient has senile degenerative aortic valve stenosis confirmed by echocardiographically derived criteria\*:

* An initial aortic valve area (AVA) of less than or equal to (≤) 1.0 cm2 (or indexed EOA less than or equal to (≤) 0.6 cm2/m2) AND
* A mean gradient greater than (\>)40 mmHg or jet velocity greater than (\>)4.0 m/s or Doppler Velocity Index less than (\<)0.25. If the mean gradient is \<40 mmHg and left ventricular ejection fraction (LVEF) \<55%, then the site may as well perform a dobutamine stress echo to see if the mean gradient increases to \>40 mmHg." (Baseline measurement taken by echo within 6 months of index procedure.)
* Patient has a life expectancy more than (\>) 12 months.

For patients enrolled in a French site:

* Patient is at high risk for surgery as demonstrated by a Logistic EuroSCORE equal or more than (≥) 20 and/or a Society of Thoracic Surgeon (STS) mortality risk score of more than (\>) 10% and/or by clinical judgment of the Heart Team based on the individual risk profile (comorbidities).

* Not applicable for a patient who has received a Portico Valve as per participation in an SJM sponsored Regulatory or First-In-Human trial.

Exclusion Criteria

* Any case in which the Portico Valve would not be indicated for the patient as per current instructions for use (i.e any "off-label" use).
* Patient has any other aortic valve than tricuspid one.
* Patient has a prosthetic valve or ring in the aortic position.
* Patient needs a concomitant structural heart procedure..
* Patient needs the usage of an embolic protection device.
* Patient is unwilling or unable to comply with all clinical investigation-required follow-up evaluations.
* Patient is pregnant
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott Medical Devices

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Francesco Maisano, MD

Role: PRINCIPAL_INVESTIGATOR

San Raffaele Hospital

Stephen Worthley

Role: PRINCIPAL_INVESTIGATOR

St Andrews Hospital

Josep Rodes-Cabau

Role: PRINCIPAL_INVESTIGATOR

Institut de Cardiologie de Quebec (Hospital Laval)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Royal Adelaide Hospital

Adelaide, , Australia

Site Status

St Andrews Hospital

Adelaide, , Australia

Site Status

Heart Care Partners-Wesley Hospital

Auchenflower, , Australia

Site Status

The Prince Charles Hospital

Chermside, , Australia

Site Status

Royal North Shore hospital

Leonards Hill, , Australia

Site Status

The Alfred Hospital

Melbourne, , Australia

Site Status

Royal Melbourne Hospital - City Campus

Parkville, , Australia

Site Status

Fiona Stanley Hospital

Perth, , Australia

Site Status

North Shore Private Hospital

St Leonards, , Australia

Site Status

Princess Alexandra Hospital

Woolloongabba, , Australia

Site Status

AZ Middelheim

Antwerp, , Belgium

Site Status

Cliniques Universitaires Saint-Luc

Brussels, , Belgium

Site Status

CHR Citadelle

Liège, , Belgium

Site Status

Foothills Medical Centre

Calgary, , Canada

Site Status

Queen Elizabeth II Heath Sciences

Halifax, , Canada

Site Status

Institut de Cardiologie de Montreal (Montreal Heart Inst.)

Montreal, , Canada

Site Status

Ottawa Heart Institute

Ottawa, , Canada

Site Status

Institut de Cardiologie de Quebec (Hospital Laval)

Québec, , Canada

Site Status

Saint John Regional Hospital - New Brunswick Heart Centre

Saint John, , Canada

Site Status

Toronto General Hospital

Toronto, , Canada

Site Status

St. Paul's Hospital

Vancouver, , Canada

Site Status

Rigshospitalet

Copenhagen, , Denmark

Site Status

CHRU Hopital de Pontchaillou

Rennes, , France

Site Status

CHU Rangueil Toulouse

Toulouse, , France

Site Status

Clinique Pasteur Toulouse

Toulouse, , France

Site Status

Kerckhoff-Klinik gGmbH

Bad Nauheim, , Germany

Site Status

Deutsches Herzzentrum Berlin

Berlin, , Germany

Site Status

Universitatsmedizin Berlin - Campus Benjamin Franklin (CBF)

Berlin, , Germany

Site Status

Immanuelklinikum Bernau und Herzzentrum Brandenburg

Bernau, , Germany

Site Status

St Johannes Hospital

Dortmund, , Germany

Site Status

Herzzentrum Dresden GmbH Universitatsklinik

Dresden, , Germany

Site Status

Klinikum der Johann Wolfgang Goethe-Universitat Frankfurt

Frankfurt, , Germany

Site Status

Universitatsmedizin Gottingen Georg-August-Universitat

Göttingen, , Germany

Site Status

Asklepios Klinikum St Georg

Hamburg, , Germany

Site Status

UKE Hamburg (Universitatsklinik Eppendorf)

Hamburg, , Germany

Site Status

Universitatsklinikum Jena

Jena, , Germany

Site Status

Stadtisches Klinikum Karlsruhe gGmbH Medizinischen Klinik I

Karlsruhe, , Germany

Site Status

Herzzentrum Leipzig GmbH

Leipzig, , Germany

Site Status

Deutsches Herzzentrum Munchen des Freistaates Bayern

München, , Germany

Site Status

Kaplan Medical Center

Rehovot, , Israel

Site Status

Clinica Citta di Alessandria

Alessandria, , Italy

Site Status

Azienda Ospedali V. Emanuele Ferrarotto E S. Bambino

Catania, , Italy

Site Status

Fondazione Toscana Gabriele Monasterio - Ospedale del Cuore

Massa, , Italy

Site Status

Istituto Sant'Ambrogio

Milan, , Italy

Site Status

Ospedale Niguarda Ca'Granda

Milan, , Italy

Site Status

Ospedale San Raffaele

Milan, , Italy

Site Status

PoliclinicoSan Donato

Milan, , Italy

Site Status

Centro Cardiologico Monzino

Milan, , Italy

Site Status

Policlinico di Monza

Monza, , Italy

Site Status

Vilnius University Hospital Santarisku KLinikos

Vilnius, , Lithuania

Site Status

OLVG

Amsterdam, , Netherlands

Site Status

Medisch Centrum Leeuwarden

Leeuwarden, , Netherlands

Site Status

Hospital de la Santa Creu I Sant Pau

Barcelona, , Spain

Site Status

Hospital Clinico Universitario Virgen de Arrixaca

El Palmar, , Spain

Site Status

Hospital Universitario Virgen Macarena

Seville, , Spain

Site Status

Universitatspital Spital Zurich

Zurich, , Switzerland

Site Status

Royal Victoria Hospital

Belfast, , United Kingdom

Site Status

The Royal Sussex Country Hospital

Brighton, , United Kingdom

Site Status

Kings College Hospital

London, , United Kingdom

Site Status

Morriston hospital-ABM University Health Board

Morriston, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia Belgium Canada Denmark France Germany Israel Italy Lithuania Netherlands Spain Switzerland United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Puri R, Thiele H, Fichtlscherer S, Westermann D, Makkar R, Waksman R, Hakmi S, Sondergaard L, Groh M, Montarello JK, Kempfert J, Yong G, Bedogni F, Maisano F, Worthley SG, Rodes-Cabau J, Fontana GP, Mollmann H. Five-Year Clinical Outcomes and Durability of a Self-Expanding Transcatheter Heart Valve With Intra-Annular Leaflets. Circ Cardiovasc Interv. 2025 Oct 24:e015430. doi: 10.1161/CIRCINTERVENTIONS.125.015430. Online ahead of print.

Reference Type DERIVED
PMID: 41133305 (View on PubMed)

Sondergaard L, Rodes-Cabau J, Hans-Peter Linke A, Fichtlscherer S, Schafer U, Kuck KH, Kempfert J, Arzamendi D, Bedogni F, Asch FM, Worthley S, Maisano F. Transcatheter Aortic Valve Replacement With a Repositionable Self-Expanding Prosthesis: The PORTICO-I Trial 1-Year Outcomes. J Am Coll Cardiol. 2018 Dec 11;72(23 Pt A):2859-2867. doi: 10.1016/j.jacc.2018.09.014. Epub 2018 Sep 24.

Reference Type DERIVED
PMID: 30261238 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CV-12-054-EU-PV

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Portico Next Generation Approval Study
NCT04011722 ACTIVE_NOT_RECRUITING NA